Regeneron Pharmaceuticals, Inc. (REGN)
Automate Your Wheel Strategy on REGN
With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REGN
- Rev/Share 139.3868
- Book/Share 367.4548
- PB 2.066
- Debt/Equity 0.0716
- CurrentRatio 36.5074
- ROIC 0.0848
- MktCap 78409870179.0
- FreeCF/Share 40.3722
- PFCF 18.8744
- PE 17.341
- Debt/Assets 0.0667
- DivYield 0.0046
- ROE 0.1407
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | REGN | BofA Securities | Underperform | Buy | -- | $860 | Jan. 7, 2026 |
| Downgrade | REGN | Morgan Stanley | Overweight | Equal Weight | -- | $767 | Dec. 3, 2025 |
| Resumed | REGN | Truist | -- | Buy | -- | $798 | Nov. 24, 2025 |
| Initiation | REGN | HSBC Securities | -- | Buy | -- | $255 | Nov. 24, 2025 |
| Initiation | REGN | Scotiabank | -- | Sector Perform | -- | $650 | Nov. 13, 2025 |
| Initiation | REGN | Rothschild & Co Redburn | -- | Buy | -- | $890 | Aug. 14, 2025 |
| Downgrade | REGN | Argus | Buy | Hold | -- | -- | June 30, 2025 |
| Downgrade | REGN | Wells Fargo | Overweight | Equal Weight | -- | $580 | May 30, 2025 |
| Downgrade | REGN | RBC Capital Mkts | Outperform | Sector Perform | -- | $662 | May 30, 2025 |
| Upgrade | REGN | Citigroup | Neutral | Buy | -- | $700 | May 14, 2025 |
News
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Published: January 30, 2026 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Read More
Regeneron bets added cholesterol benefit will help its obesity drug stand out
Published: January 30, 2026 by: Reuters
Sentiment: Positive
Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly crowded obesity market.
Read More
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
REGN beats Q4 earnings estimates as Eylea HD and Dupixent profits lift revenues, though higher expenses drive a year-over-year EPS decline.
Read More
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings?
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
REGN's Q4 report could hinge on Dupixent profit growth and strong Eylea HD uptake as legacy Eylea sales face competitive pressure.
Read More
Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive
Regeneron Pharmaceuticals, Inc. is approaching a pivotal earnings report following a strong JP Morgan Healthcare Conference update. I maintain a Buy rating on REGN, supported by a >16% share price gain since my last note. Despite recent gains, REGN trades well below its ~$1,200 all-time high from August 2024.
Read More
REGN or ILMN: Which Is the Better Value Stock Right Now?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
Published: January 21, 2026 by: GlobeNewsWire
Sentiment: Neutral
Society for Science & Regeneron announced the finalists in the Regeneron Science Talent Search, the nation's oldest and most prestigious STEM competition
Read More
Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalysts
Published: January 07, 2026 by: Proactive Investors
Sentiment: Positive
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been upgraded by Bank of America, which raised its rating on the biotechnology company to ‘Buy' from ‘Underperform' and increased its price objective to $860 from $627, citing improving fundamentals across key products and multiple potential catalysts in 2026. Shares of Regeneron traded up 3.5% at about $803 on Wednesday afternoon.
Read More
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
REGN vs. ILMN: Which Stock Is the Better Value Option?
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
REGN vs. ILMN: Which Stock Should Value Investors Buy Now?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
Read More
Regeneron (REGN) Just Flashed Golden Cross Signal: Do You Buy?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Read More
Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv
Published: December 10, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Published: December 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Read More
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
Published: December 10, 2025 by: Reuters
Sentiment: Positive
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow transplants, preliminary data from a small mid-stage trial suggest.
Read More
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Published: December 08, 2025 by: Seeking Alpha
Sentiment: Positive
Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion remaining under its authorized share repurchase program, underscoring its ongoing efforts to create long-term value for its investors. However, I believe the European Commission's approval of Dupixent for the treatment of chronic spontaneous urticaria on November 25 is even more important.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
Read More
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
Read More
Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?
Read More
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
Read More
This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead
Published: November 21, 2025 by: Investopedia
Sentiment: Neutral
November's Wall Street obsession hasn't been AI. It's been healthcare.
Read More
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. ( REGN ) Jefferies London Healthcare Conference 2025 November 17, 2025 10:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Thanks so much, everyone. It's funny.
Read More
About Regeneron Pharmaceuticals, Inc. (REGN)
- IPO Date 1991-04-02
- Website https://www.regeneron.com
- Industry Biotechnology
- CEO Leonard S. Schleifer
- Employees 15158